Including today's surge, Summit shares have risen more than 35% this year. U.S.-listed shares of AstraZeneca, which fell 2.5% in recent trading to pace Nasdaq decliners Thursday, are up about 6% ...

AstraZeneca is in talks with Summit Therapeutics to license an experimental lung-cancer drug under a deal worth as much as $15 billion, Bloomberg News reported on Thursday, citing people familiar ...

Well before market open that day, Leerink Partners' Daina Graybosch initiated coverage on Summit stock. According to reports, Graybosch focused on ivonescimab, the high-profile cancer drug that ...

In the most recent trading session, Stellantis (STLA) closed at $9.8, indicating a -4.95% shift from the previous trading day.

Join us at the 4th Inner Ear Disorders Therapeutics Summit to explore the latest advances in regenerative therapies from industry leaders like Regeneron, Refreshgene Therapeutics, and Spiral ...

Nektar Therapeutics shares doubled in early trading Tuesday after the U.S. biotech firm said it reached its targets in a midstage study of its eczema treatment.

It has looked externally to scale up its presence, and the EsoBiotec deal follows a $1.2 billion takeover of CAR-T therapy developer Gracell Biotechnologies in late 2023 and a $2 billion ...

SAN DIEGO--(BUSINESS WIRE)--Candid Therapeutics, Inc. (“Candid”), a clinical-stage biotechnology company redefining the treatment of autoimmune and inflammatory diseases through novel T-cell ...